ProKidney Corp. (PROK) saw its shares rise 371.7% over the last three months, significantly outperforming the S&P 500’s 18.2% growth. The clinical-stage biotechnology company holds a Zacks Rank #1, with the Zacks Consensus Estimate for its earnings increasing by 5.8% in the past 60 days.
Roku, Inc. (ROKU) experienced a 55.4% gain in shares over the last three months, also exceeding the S&P 500’s 18.2% rise. The streaming platform operator, which has a Zacks Rank #1, reported a 5.3% increase in the Zacks Consensus Estimate for its current year earnings in the prior two months.
Pharming Group N.V. (PHAR) shares climbed 26.6% in the past three months, surpassing the S&P 500 gains. This biopharmaceutical company, holding a Zacks Rank #1, saw its earnings estimate increase nearly 7% over the last 60 days.
